Repository logo


Cerebral monoamine oxidase a inhibition in tobacco smokers confirmed with PET and [c-11]befloxatone

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Lippincott, Williams & Wilkins

Abstract

The inhibition of cerebral monoamine oxidases (MAOs) by cigarette smoke components could participate to the tobacco addiction. However, the actual extent of this inhibition in vivo in smokers is still poorly known. We investigated cerebral MAO-A availability in 7 tobacco-dependent subjects and 6 healthy nonsmokers, using positron emission tomography (PET) and the MAO-A selective radioligand [11C]befloxatone. In comparison to nonsmokers, smokers showed a significant overall reduction of [11C]befloxatone binding potential (BP) in cortical areas (average reduction, -60%) and a similar trend in caudate and thalamus (-40%). Our findings confirm a widespread inhibition of cerebral MAO-A in smokers. This mechanism may contribute to tobacco addiction and for a possible mood-modulating effect of tobacco. © 2009, Lippincott, Williams & Wilkins

Description

Citation

Leroy, C., Bragulat, V., Berlin, I., Grégoire, M. C., Bottlaender, M., Roumenov, D., Dolle, F., Bourgeois, S., Penttilae, J., Artiges, E., Martinot, J. L., & Trichard, C. (2009). Cerebral monoamine oxidase a inhibition in tobacco smokers confirmed with PET and [c-11]befloxatone. Journal of Clinical Psychopharmacology, 29(1), 86-88. doi:10.1097/JCP.0b013e31819e98f

Collections

Endorsement

Review

Supplemented By

Referenced By